Author

Emma Louise Arriola

Observed names: E L Arriola, E. Arriola, Emma Arriola, Emma L Arriola, Emma L. Arriola

Institutions: AbbVie (United States), AbbVie (United Kingdom)

Observed institutions: Institute of Cancer Research, Royal Bournemouth Hospital, University of Manchester, AbbVie (United States), University Hospital Schleswig-Holstein, AbbVie (United Kingdom), The University of Texas at Austin, Universidad Nacional Autónoma de México

OpenAlex ID: A5042397037

The BCL11 gene family: involvement of BCL11A in lymphoid malignancies

2001 · Ed Satterwhite, Takashi Sonoki, et al. · Blood · 314

Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis

1999 · Emma L Arriola, Ana M Rodriguez-Lopez, et al. · Oncogene · 79

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop

1999 · Emma L Arriola, Ana Rodriguez Lopez, et al. · Oncogene · 58

Apoptosis and Cancer Chemotherapy

1999 · C M Chresta, E L Arriola, et al. · Humana Press eBooks · 46

p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma

1998 · Pedro Luna-Perez, Emma L. Arriola, et al. · Annals of Surgical Oncology · 45

A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

2021 · Cristina Gasparetto, Kristian M. Bowles, et al. · Clinical Lymphoma Myeloma & Leukemia · 20

A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.

2020 · Maria-Victoria Mateos, Philippe Moreau, et al. · Journal of Clinical Oncology · 17

Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.

2024 · Nizar J. Bahlis, Rakesh Popat, et al. · Journal of Clinical Oncology · 14

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

2025 · Rakesh Popat, Meral Beksac, et al. · Journal of Clinical Oncology · 6

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

2025 · Rajshekhar Chakraborty, Efstathios Kastritis, et al. · Blood · 4

2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma

2015 · S. Fischer, T. Tandstad, et al. · European Journal of Cancer · 1

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

2021 · Sudeep Karve, Shaji Kumar, et al. · Blood

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

2021 · Nnadozie Emechebe, Shaji Kumar, et al. · Blood

Onartuzumab. Anti-HGFR (c-Met) monoclonal antibody, oncolytic

2014 · E. Arriola, D. Conde-Estévez · Drugs of the Future

Works count: 14

Citation count: 604

H-index: 8

I10-index: 8